Response to: 'Denosumab, cortical bone and bone erosion in rheumatoid arthritis' by Rossini et al
Ann Rheum Dis
.
2016 Oct;75(10):e71.
doi: 10.1136/annrheumdis-2016-210027.
Epub 2016 Aug 23.
Authors
Tsutomu Takeuchi
1
,
Yoshiya Tanaka
2
,
Naoki Ishiguro
3
,
Hisashi Yamanaka
4
,
Toshiyuki Yoneda
5
,
Takeshi Ohira
6
,
Naoki Okubo
6
,
Harry K Genant
7
,
Désirée van der Heijde
8
Affiliations
1
Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
2
First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
3
Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine, Aichi, Japan.
4
Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan.
5
Division of Hematology/Oncology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
6
Daiichi-Sankyo Co., Ltd., Tokyo, Japan.
7
Departments of Radiology, Medicine and Orthopaedic Surgery, University of California, San Francisco, California, USA.
8
Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands.
PMID:
27553215
DOI:
10.1136/annrheumdis-2016-210027
No abstract available
Keywords:
Osteoporosis; Rheumatoid Arthritis; Treatment.
Publication types
Letter
Comment
MeSH terms
Arthritis, Rheumatoid*
Bone and Bones
Cortical Bone
Denosumab*
Humans
Osteoporosis
Substances
Denosumab